Business Context and Reporting Period
Company: Chemed Corporation (CHEMED)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2007
Business Overview: Chemed operates through two primary segments: VITAS Healthcare (hospice care) and Roto-Rooter Group (plumbing and drain cleaning services).
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Jun 30, 2007 |
6 Months Ended Jun 30, 2007 |
6 Months Ended Jun 30, 2006 |
|---|---|---|---|
| Service Revenues & Sales | $271,387 | $541,826 | $492,989 |
| Income from Continuing Ops | $9,433 | $25,654 | $25,588 |
| Net Income | $9,433 | $25,654 | $25,057 |
| Diluted EPS (Continuing Ops) | $0.38 | $1.00 | $0.95 |
| Operating Cash Flow | N/A | $30,224 | $23,485 |
| Cash & Equivalents (End Period) | $7,469 | $7,469 | $6,816 |
| Total Debt (Current + Long-Term) | $278,197 | $278,197 | $150,540 |
| Unused Revolving Credit | $127.4 million | $127.4 million | N/A |
Margins (6 Months 2007 vs 2006):
- Consolidated Gross Margin: 30.4% (vs 28.0%)
- VITAS Gross Margin: 22.5% (vs 19.9%)
- Roto-Rooter Gross Margin: 47.6% (vs 45.4%)
Material Changes vs. Prior Period
- Revenue Growth: Consolidated revenue increased 9.0% in Q2 and 9.9% for the six months ended June 30, 2007, compared to the prior year. VITAS revenue grew 8% (Q2) and 10% (6M), driven by a 7-9% increase in Average Daily Census (ADC) and Medicare rate increases. Roto-Rooter revenue grew 11% (Q2 and 6M), driven by price/mix changes and job count increases.
- Profitability Impact: While operating income increased due to higher sales and improved gross margins, Net Income for Q2 2007 decreased 26.5% compared to Q2 2006. This decline was primarily caused by a $13.7 million loss on extinguishment of debt related to refinancing activities.
- Debt Restructuring: The company significantly altered its capital structure in May 2007. It entered a new $375 million credit facility, redeemed $150 million of 8.75% Senior Notes, and issued $200 million of 1.875% Senior Convertible Notes. This reduced the overall borrowing rate but incurred significant one-time costs.
- Share Repurchases: The company repurchased approximately 2.1 million shares during the first six months of 2007, utilizing proceeds from the convertible note issuance.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items: The $13.7 million loss on extinguishment of debt is a non-recurring item comprising a $6.6 million premium on note redemption and $7.1 million in write-offs of deferred debt costs. Additionally, $8.5 million in stock-based compensation expense was recorded in the first six months of 2007 (vs. negligible amounts in 2006) due to LTIP payouts and option grants.
- Liquidity: Management believes liquidity is satisfactory. As of June 30, 2007, the company had $127.4 million in unused revolving credit available. Cash and cash equivalents decreased to $7.5 million due to debt repayments and share buybacks.
- Risks and Contingencies:
- Medicare Cap: VITAS monitors programs for potential Medicare billing caps. No cap liability was recorded for the period ended June 30, 2007, though estimates for the full year anticipate no limitations.
- Litigation: VITAS faces class-action lawsuits in California regarding wage and hour violations (Costa and Santos cases). A $19.9 million settlement was approved in the Costa case; the Santos case is in early stages with unestimable liability.
- OIG Investigation: The Office of Inspector General is investigating VITAS' billing practices. A related qui tam complaint was dismissed in July 2007, but the government investigation continues. The company cannot predict the outcome or financial impact.
- Outlook: No specific forward-looking financial guidance was provided in this filing. Management noted that the refinancing transactions were designed to reduce borrowing costs and shares outstanding.
Investor Verification Checklist
- Debt Covenants: Verify continued compliance with the new 2007 Facility covenants, particularly leverage ratios, given the increased debt load.
- Convertible Note Dilution: Monitor the stock price relative to the $80.73 conversion price of the new 1.875% Senior Convertible Notes to assess potential future dilution.
- Medicare Cap Exposure: Review future filings for any accruals related to the Medicare cap, as this can significantly impact VITAS revenue recognition.
- Litigation Reserves: Track developments in the California wage/hour class actions and the OIG investigation for potential reserve increases.
- Cash Position: Monitor the low cash balance ($7.5 million) relative to the current portion of long-term debt ($10.2 million) and upcoming interest payments.